Rani Therapeutics Holdings, Inc. (RANI)
| Market Cap | 109.79M +192.0% |
| Revenue (ttm) | 1.63M +58.9% |
| Net Income | -29.67M |
| EPS | -0.45 |
| Shares Out | 99.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,076,509 |
| Open | 1.080 |
| Previous Close | 1.070 |
| Day's Range | 1.020 - 1.120 |
| 52-Week Range | 0.387 - 3.870 |
| Beta | 0.76 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+581.82%) |
| Earnings Date | May 26, 2026 |
About RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in prec... [Read more]
Financial Performance
In 2025, RANI's revenue was $1.63 million, an increase of 58.85% compared to the previous year's $1.03 million. Losses were -$29.67 million, -1.15% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for RANI stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 581.82% from the latest price.
News
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv...
Rani Therapeutics price target lowered to $5 from $9 at Canaccord
Canaccord lowered the firm’s price target on Rani Therapeutics (RANI) to $5 from $9 and keeps a Buy rating on the shares. The firm updated its model after the company…
Rani Therapeutics Holdings Earnings Call Transcript: Q4 2025
Significant progress was made in 2025, including a major Chugai partnership, strong pipeline advances, and improved financials with a cash runway into Q4 2027. RT-114 entered phase I trials, and the company is now debt-free.
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapita...
Rani Therapeutics Holdings options imply 17.3% move in share price post-earnings
Pre-earnings options volume in Rani Therapeutics (RANI) Holdings is 1.1x normal with calls leading puts 24:1. Implied volatility suggests the market is anticipating a move near 17.3%, or 20c, after…
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv...
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv...
Rani Therapeutics promotes Javadi to Chief Technical Officer
Rani Therapeutics (RANI) announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer. Prior to the promotion to Chief Technical Officer, Alireza served as Vice President, Technical Op...
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...
Rani Therapeutics initiates Phase 1 study of RT-114 RaniPill
Rani Therapeutics (RANI) announced the initiation of a Phase 1 clinical trial to evaluate the safety, tolerability, bioavailability, and pharmacokinetics and pharmacodynamics of single and multiple do...
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill® capsule versus subcutaneou...
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Polestar Automotive (PSNY) 211.69% +5.90, Rani Therapeutics Holdings (RANI) 40.71% +4.91, MSOX ETF (MS...
Rani Therapeutics to Participate in the Evercore Healthcare Conference
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...
Rani Therapeutics files to sell 42.63M shares of Class A common stock for holder
17:13 EST Rani Therapeutics (RANI) files to sell 42.63M shares of Class A common stock for holder
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics –
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Kodiak AI, Inc. Common Stock (KDK) 68.06% +4.94, Rani Therapeutics Holdings (RANI) 83.37% +1.53, DEFIA...
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr.
Unusually active option classes on open October 21st
Unusual total active option classes on open include: Beyond Meat (BYND), Rani Therapeutics Holdings (RANI), 3M (MMM), Coca Cola (KO), Clover Health (CLOV), Stratasys (SSYS), Consumer Discretionary Sec...
Rani Therapeutics assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics (RANI) with a Buy rating and $11 price target The firm believes the company has “three significant value drivers,” its…
Rani Therapeutics price target raised to $10 from $5 at Maxim
Maxim raised the firm’s price target on Rani Therapeutics (RANI) to $10 from $5 and keeps a Buy rating on the shares after the company announced a licensing deal with…
CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why
Biotech stocks are lighting up the tape today, with several clinical-stage companies posting double-digit gains on fresh catalysts. From earnings beats to promising trial data and billion-dollar partn...
Why This Penny Biotech Stock Is Still Climbing After a 250% Surge
Rani Therapeutics Holdings ($RANI), a clinical-stage penny biotech stock, soared nearly 250% on Friday and continued to trade higher in pre-market trading on Monday following last week’s sharp rally. ...
Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma
Rani Therapeutics said on Friday it has agreed a deal to license an oral drug to Japan's Chugai Pharmaceutical , with an option to extend it to up to five drugs, potentially bringing the total deal va...